ADPT vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while ADPT counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, ADPT trades at N/M Forward P/E with -16.2% operating margin (-10.7% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, ADPT sits in BREAKOUT (36th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ADPT Revenue | MRNA Revenue | ADPT Op. Margin | MRNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $60M | $140M | -89.4% | -306.0% | ADPT |
| FY2019 | $90M | $60M | -92.1% | -906.8% | ADPT |
| FY2020 | $100M | $800M | -155.3% | -95.0% | MRNA |
| FY2021 | $150M | $18.5B | -135.4% | 72.0% | MRNA |
| FY2022 | $190M | $19.3B | -108.0% | 48.9% | MRNA |
| FY2023 | $170M | $6.85B | -133.3% | -61.9% | MRNA |
| FY2024 | $180M | $3.24B | -90.8% | -121.9% | ADPT |
| FY2025 | $280M | $1.94B | -20.6% | -158.1% | ADPT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ADPT | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $90.4B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | -10.7% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -16.2% | -80.8% | Higher Margin | ADPT |
| Net Profit Margin Profitability | -23.7% | -110.5% | Higher Margin | ADPT |
| Return on Equity (ROE) Capital Efficiency | -36.4% | -34.5% | Higher ROE | MRNA |
| 52-Week Range Position Momentum | 81% ($12โ$32) | 71% ($22โ$281) | Stronger Trend | ADPT |
| Beta / 30D Volatility Risk Regime | 1.71ฮฒ ยท 59% Vol | 2.37ฮฒ ยท 100% Vol | Lower Realized Risk | ADPT |
| Unified Institutional Score Composite Signal | 43.2 / 100 (HOLD) | 46.6 / 100 (HOLD) | Higher Composite | MRNA |